New hope for kids with tough cancers: immunotherapy combo under study
NCT ID NCT03837899
First seen Apr 22, 2026 · Last updated Apr 30, 2026 · Updated 3 times
Summary
This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or certain blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs can shrink tumors. The goal is to control the disease, not cure it, as ongoing treatment may be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Baltimore, Maryland, 21231, United States
-
Research Site
Boston, Massachusetts, 02115, United States
-
Research Site
New Hyde Park, New York, 11040, United States
-
Research Site
Oklahoma City, Oklahoma, 73104, United States
-
Research Site
Charleston, South Carolina, 29425, United States
-
Research Site
Lille, 59020, France
-
Research Site
Marseille, 13385, France
-
Research Site
Paris, 75248, France
-
Research Site
Cologne, 50924, Germany
-
Research Site
Genova, 16100, Italy
-
Research Site
Milan, 20133, Italy
-
Research Site
Rome, 00165, Italy
-
Research Site
Torino, 10126, Italy
-
Research Site
Utrecht, 3584 CS, Netherlands
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Madrid, 28009, Spain
-
Research Site
Leeds, LS1 3EX, United Kingdom
-
Research Site
London, WC1N 3JH, United Kingdom
-
Research Site
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.